FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1510109991> ?p ?o ?g. }

• W1510109991 endingPage "859" @default.
• W1510109991 startingPage "851" @default.
• W1510109991 abstract "Patients presenting to emergency departments (ED) with nonspecific complaints (NSCs) such as not feeling well,feeling weak,being tired,general deterioration, or other similar chief complaints that do not have a readily identifiable probable etiology are a common patient group at risk for adverse outcomes. Certain biomarkers, which have not yet been tested for prognostic value when applied to ED patients with NSCs, have emerged as useful tools for predicting prognosis in patients with a variety of diseases. This study tested the hypothesis that two of these novel markers, copeptin (a C-terminal portion of provasopressin) and/or peroxiredoxin-4 (Prx4), an enzyme that degrades hydrogen peroxide, singly or together are helpful in predicting death in the near term among patients presenting to the ED with NSCs.The Basel Non-specific Complaints (BANC) study is a delayed type cross-sectional diagnostic study with a prospective 30-day follow-up. ED patients with NSCs were consecutively enrolled. Patients with vital parameters out of the normal range were excluded. The primary endpoint of this study was the predictive value of copeptin and Prx4 for 30-day mortality in patients with NSCs. Measurement of both copeptin and Prx4 was performed in serum samples with sandwich immunoluminometric assays.On follow-up at 30 days after ED presentation, 28 of 438 patients with NSC had died. Copeptin and Prx4 concentrations were significantly higher in nonsurvivors than in survivors (Kruskal-Wallis test, p = 0.0001 and p < 0.0001, respectively). In univariate models, Prx4 (likelihood ratio [LR] χ(2) = 22.24, p < 0.00001, concordance index [C-index] = 0.749) and copeptin (LR χ(2) = 16.98, p = 0.00004, C-index = 0.724) were both predictive of 30-day mortality, and elevated levels were associated with an increased mortality. The bivariable model, which included both Prx4 and copeptin (LR χ(2) = 28.22, p < 0.00001, C-index = 0.783), allows a significantly better prediction than the univariate Prx4 (p = 0.00025) and copeptin models (p = 0.00099), respectively. Both biomarkers provided independent and additional information to clinical risk scores (Katz Activities of Daily Living [ADL] and Charlson Comorbidity Index [CCI], all p < 0.0005).Copeptin and Prx4 are new prognostic markers in patients presenting to the ED with NSCs. Copeptin and Prx4 might be valuable tools for risk stratification and decision-making in this patient group." @default.
• W1510109991 created "2016-06-24" @default.
• W1510109991 creator A5011568032 @default.
• W1510109991 creator A5012726033 @default.
• W1510109991 creator A5017233091 @default.
• W1510109991 creator A5017372231 @default.
• W1510109991 creator A5039567211 @default.
• W1510109991 creator A5052536282 @default.
• W1510109991 creator A5062437739 @default.
• W1510109991 creator A5064985195 @default.
• W1510109991 creator A5068485916 @default.
• W1510109991 creator A5080720643 @default.
• W1510109991 date "2011-08-01" @default.
• W1510109991 modified "2023-10-17" @default.
• W1510109991 title "Copeptin and Peroxiredoxin-4 Independently Predict Mortality in Patients With Nonspecific Complaints Presenting to the Emergency Department" @default.
• W1510109991 cites W1964449752 @default.
• W1510109991 cites W1969491266 @default.
• W1510109991 cites W1973162556 @default.
• W1510109991 cites W2000445173 @default.
• W1510109991 cites W2022792673 @default.
• W1510109991 cites W2027338356 @default.
• W1510109991 cites W2028781991 @default.
• W1510109991 cites W2030318378 @default.
• W1510109991 cites W2035713858 @default.
• W1510109991 cites W2042355814 @default.
• W1510109991 cites W2048005287 @default.
• W1510109991 cites W2054311013 @default.
• W1510109991 cites W2060858687 @default.
• W1510109991 cites W2062071013 @default.
• W1510109991 cites W2071844523 @default.
• W1510109991 cites W2071981414 @default.
• W1510109991 cites W2079248558 @default.
• W1510109991 cites W2079300508 @default.
• W1510109991 cites W2088794031 @default.
• W1510109991 cites W2091020688 @default.
• W1510109991 cites W2097682151 @default.
• W1510109991 cites W2105924651 @default.
• W1510109991 cites W2106364045 @default.
• W1510109991 cites W2120658378 @default.
• W1510109991 cites W2123664981 @default.
• W1510109991 cites W2140162404 @default.
• W1510109991 cites W2144352652 @default.
• W1510109991 cites W2144687835 @default.
• W1510109991 cites W2154997944 @default.
• W1510109991 cites W2158496331 @default.
• W1510109991 cites W2159421709 @default.
• W1510109991 cites W2162903744 @default.
• W1510109991 cites W2165201727 @default.
• W1510109991 cites W2167996222 @default.
• W1510109991 cites W2168994566 @default.
• W1510109991 cites W4256436395 @default.
• W1510109991 doi "https://doi.org/10.1111/j.1553-2712.2011.01126.x" @default.
• W1510109991 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21843221" @default.
• W1510109991 hasPublicationYear "2011" @default.
• W1510109991 type Work @default.
• W1510109991 sameAs 1510109991 @default.
• W1510109991 citedByCount "39" @default.
• W1510109991 countsByYear W15101099912012 @default.
• W1510109991 countsByYear W15101099912013 @default.
• W1510109991 countsByYear W15101099912014 @default.
• W1510109991 countsByYear W15101099912015 @default.
• W1510109991 countsByYear W15101099912016 @default.
• W1510109991 countsByYear W15101099912017 @default.
• W1510109991 countsByYear W15101099912018 @default.
• W1510109991 countsByYear W15101099912019 @default.
• W1510109991 countsByYear W15101099912020 @default.
• W1510109991 countsByYear W15101099912021 @default.
• W1510109991 crossrefType "journal-article" @default.
• W1510109991 hasAuthorship W1510109991A5011568032 @default.
• W1510109991 hasAuthorship W1510109991A5012726033 @default.
• W1510109991 hasAuthorship W1510109991A5017233091 @default.
• W1510109991 hasAuthorship W1510109991A5017372231 @default.
• W1510109991 hasAuthorship W1510109991A5039567211 @default.
• W1510109991 hasAuthorship W1510109991A5052536282 @default.
• W1510109991 hasAuthorship W1510109991A5062437739 @default.
• W1510109991 hasAuthorship W1510109991A5064985195 @default.
• W1510109991 hasAuthorship W1510109991A5068485916 @default.
• W1510109991 hasAuthorship W1510109991A5080720643 @default.
• W1510109991 hasBestOaLocation W15101099911 @default.
• W1510109991 hasConcept C118552586 @default.
• W1510109991 hasConcept C126322002 @default.
• W1510109991 hasConcept C137627325 @default.
• W1510109991 hasConcept C144301174 @default.
• W1510109991 hasConcept C188816634 @default.
• W1510109991 hasConcept C194828623 @default.
• W1510109991 hasConcept C203092338 @default.
• W1510109991 hasConcept C2776370428 @default.
• W1510109991 hasConcept C2779311642 @default.
• W1510109991 hasConcept C2780724011 @default.
• W1510109991 hasConcept C38180746 @default.
• W1510109991 hasConcept C535046627 @default.
• W1510109991 hasConcept C71924100 @default.
• W1510109991 hasConceptScore W1510109991C118552586 @default.
• W1510109991 hasConceptScore W1510109991C126322002 @default.
• W1510109991 hasConceptScore W1510109991C137627325 @default.
• W1510109991 hasConceptScore W1510109991C144301174 @default.
• W1510109991 hasConceptScore W1510109991C188816634 @default.
• W1510109991 hasConceptScore W1510109991C194828623 @default.

• next